Communiqués Genelux Corporation

Actions

GNLX

US36870H1032

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 16:59:34 24/09/2026			Varia. 5j.	Varia. 1 janv.
2,455 ^USD	-2,39%		-2,37%	-43,35%

09/09	Genelux Corporation publie les résultats de la phase 1b d'escalade de dose de l'essai OLVI-VEC-202-SCLC	CI
13/08	Genelux Corporation publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

09/09	Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy	GL
13/08	Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates	GL
30/06	Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer	GL
08/05	Genelux : Presentation – May 2026 (b9dbaf)	PU
08/05	Genelux : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates	GL
19/04	Genelux : Presentation – April 2026 (d85c2a)	PU
23/03	Genelux : Presentation – March 2026 (38842e)	PU
19/03	Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates	GL
18/02	Genelux Corporation to Participate in Upcoming Conferences	GL
18/02	Genelux Corporation to Participate in Upcoming Conferences	AQ
02/02	Genelux : Presentation – February 2026 (76d9ef)	PU
12/01	Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners	GL
08/01	Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock	GL
07/01	Genelux Corporation Announces Proposed Public Offering of Common Stock	GL
05/01	Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials	GL
02/01	Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer	GL
08/12	Genelux : Presentation – November 2025 (e2e98f)	PU
26/11	Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference	GL
05/11	Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates	GL
02/09/25	Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference	GL
07/08/25	Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates	GL
07/07/25	Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development	GL
07/05/25	Genelux : Corporate Presentation - May (d7b15d)	PU
06/05/25	Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates	GL